WO2014107035A1 - N-말단 전하가 변형된 인슐린 분비 펩티드 유도체 - Google Patents
N-말단 전하가 변형된 인슐린 분비 펩티드 유도체 Download PDFInfo
- Publication number
- WO2014107035A1 WO2014107035A1 PCT/KR2014/000025 KR2014000025W WO2014107035A1 WO 2014107035 A1 WO2014107035 A1 WO 2014107035A1 KR 2014000025 W KR2014000025 W KR 2014000025W WO 2014107035 A1 WO2014107035 A1 WO 2014107035A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glp
- val
- exendin
- insulin secreting
- glu
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 199
- 230000003914 insulin secretion Effects 0.000 title abstract description 42
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 claims abstract description 29
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims abstract description 29
- 230000007935 neutral effect Effects 0.000 claims abstract description 23
- 238000010494 dissociation reaction Methods 0.000 claims abstract description 16
- 230000005593 dissociations Effects 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 306
- 230000003248 secreting effect Effects 0.000 claims description 151
- 102000004877 Insulin Human genes 0.000 claims description 137
- 108090001061 Insulin Proteins 0.000 claims description 137
- 229940125396 insulin Drugs 0.000 claims description 137
- 229960001519 exenatide Drugs 0.000 claims description 93
- 108010011459 Exenatide Proteins 0.000 claims description 67
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims description 66
- 125000003277 amino group Chemical group 0.000 claims description 38
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 29
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims description 28
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 18
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 18
- 206010012601 diabetes mellitus Diseases 0.000 claims description 17
- 108010015174 exendin 3 Proteins 0.000 claims description 14
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 13
- 210000004899 c-terminal region Anatomy 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- MXNAOGFNFNKUPD-JHYOHUSXSA-N Thr-Phe-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MXNAOGFNFNKUPD-JHYOHUSXSA-N 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- -1 imidazoleacetyl residue Chemical group 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 230000004048 modification Effects 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 101800001388 Oxyntomodulin Proteins 0.000 claims description 5
- 102400000319 Oxyntomodulin Human genes 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 claims description 5
- OLVCTPPSXNRGKV-GUBZILKMSA-N Ala-Pro-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OLVCTPPSXNRGKV-GUBZILKMSA-N 0.000 claims description 4
- IIAXFBUTKIDDIP-ULQDDVLXSA-N Arg-Leu-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O IIAXFBUTKIDDIP-ULQDDVLXSA-N 0.000 claims description 4
- NCWOMXABNYEPLY-NRPADANISA-N Glu-Ala-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O NCWOMXABNYEPLY-NRPADANISA-N 0.000 claims description 4
- BUEFQXUHTUZXHR-LURJTMIESA-N Gly-Gly-Pro zwitterion Chemical compound NCC(=O)NCC(=O)N1CCC[C@H]1C(O)=O BUEFQXUHTUZXHR-LURJTMIESA-N 0.000 claims description 4
- LEHPJMKVGFPSSP-ZQINRCPSSA-N Ile-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(O)=O)=CNC2=C1 LEHPJMKVGFPSSP-ZQINRCPSSA-N 0.000 claims description 4
- WXUOJXIGOPMDJM-SRVKXCTJSA-N Leu-Lys-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O WXUOJXIGOPMDJM-SRVKXCTJSA-N 0.000 claims description 4
- GPAHWYRSHCKICP-GUBZILKMSA-N Met-Glu-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O GPAHWYRSHCKICP-GUBZILKMSA-N 0.000 claims description 4
- 108010079364 N-glycylalanine Proteins 0.000 claims description 4
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 4
- BGOWRLSWJCVYAQ-CIUDSAMLSA-N Ser-Asp-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BGOWRLSWJCVYAQ-CIUDSAMLSA-N 0.000 claims description 4
- BYCVMHKULKRVPV-GUBZILKMSA-N Ser-Lys-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O BYCVMHKULKRVPV-GUBZILKMSA-N 0.000 claims description 4
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 claims description 4
- 108010055341 glutamyl-glutamic acid Proteins 0.000 claims description 4
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 claims description 4
- 108010051307 glycyl-glycyl-proline Proteins 0.000 claims description 4
- 108010089804 glycyl-threonine Proteins 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- PAIHPOGPJVUFJY-WDSKDSINSA-N Ala-Glu-Gly Chemical group C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PAIHPOGPJVUFJY-WDSKDSINSA-N 0.000 claims description 2
- YXXPVUOMPSZURS-ZLIFDBKOSA-N Ala-Trp-Leu Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](C)N)=CNC2=C1 YXXPVUOMPSZURS-ZLIFDBKOSA-N 0.000 claims description 2
- GXCSUJQOECMKPV-CIUDSAMLSA-N Arg-Ala-Gln Chemical compound C[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O GXCSUJQOECMKPV-CIUDSAMLSA-N 0.000 claims description 2
- USNSOPDIZILSJP-FXQIFTODSA-N Arg-Asn-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O USNSOPDIZILSJP-FXQIFTODSA-N 0.000 claims description 2
- GPPIDDWYKJPRES-YDHLFZDLSA-N Asp-Phe-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O GPPIDDWYKJPRES-YDHLFZDLSA-N 0.000 claims description 2
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims description 2
- YJIUYQKQBBQYHZ-ACZMJKKPSA-N Gln-Ala-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YJIUYQKQBBQYHZ-ACZMJKKPSA-N 0.000 claims description 2
- IIMZHVKZBGSEKZ-SZMVWBNQSA-N Gln-Trp-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O IIMZHVKZBGSEKZ-SZMVWBNQSA-N 0.000 claims description 2
- XTQFHTHIAKKCTM-YFKPBYRVSA-N Gly-Glu-Gly Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O XTQFHTHIAKKCTM-YFKPBYRVSA-N 0.000 claims description 2
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 claims description 2
- NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 claims description 2
- ALSRJRIWBNENFY-DCAQKATOSA-N Lys-Arg-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O ALSRJRIWBNENFY-DCAQKATOSA-N 0.000 claims description 2
- DUTMKEAPLLUGNO-JYJNAYRXSA-N Lys-Glu-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O DUTMKEAPLLUGNO-JYJNAYRXSA-N 0.000 claims description 2
- HDNOQCZWJGGHSS-VEVYYDQMSA-N Met-Asn-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HDNOQCZWJGGHSS-VEVYYDQMSA-N 0.000 claims description 2
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 claims description 2
- BNFVPSRLHHPQKS-WHFBIAKZSA-N Ser-Asp-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O BNFVPSRLHHPQKS-WHFBIAKZSA-N 0.000 claims description 2
- HEQPKICPPDOSIN-SRVKXCTJSA-N Ser-Asp-Tyr Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HEQPKICPPDOSIN-SRVKXCTJSA-N 0.000 claims description 2
- SWSRFJZZMNLMLY-ZKWXMUAHSA-N Ser-Asp-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O SWSRFJZZMNLMLY-ZKWXMUAHSA-N 0.000 claims description 2
- XWCYBVBLJRWOFR-WDSKDSINSA-N Ser-Gln-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O XWCYBVBLJRWOFR-WDSKDSINSA-N 0.000 claims description 2
- QJKPECIAWNNKIT-KKUMJFAQSA-N Ser-Lys-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QJKPECIAWNNKIT-KKUMJFAQSA-N 0.000 claims description 2
- OLKICIBQRVSQMA-SRVKXCTJSA-N Ser-Ser-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OLKICIBQRVSQMA-SRVKXCTJSA-N 0.000 claims description 2
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 claims description 2
- 108010010147 glycylglutamine Proteins 0.000 claims description 2
- 108010078580 tyrosylleucine Proteins 0.000 claims description 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 29
- 239000008280 blood Substances 0.000 abstract description 23
- 210000004369 blood Anatomy 0.000 abstract description 23
- 230000008859 change Effects 0.000 abstract description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 4
- 102100040918 Pro-glucagon Human genes 0.000 description 26
- 230000000694 effects Effects 0.000 description 23
- 239000003814 drug Substances 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 17
- 229940079593 drug Drugs 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 230000010030 glucose lowering effect Effects 0.000 description 9
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 6
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000001766 physiological effect Effects 0.000 description 6
- 102000051325 Glucagon Human genes 0.000 description 5
- 108060003199 Glucagon Proteins 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 5
- 229960004666 glucagon Drugs 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000000586 desensitisation Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 229940084891 byetta Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 241000286209 Phasianidae Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- AHLFJIALFLSDAQ-UHFFFAOYSA-N 2-(pentylazaniumyl)acetate Chemical compound CCCCCNCC(O)=O AHLFJIALFLSDAQ-UHFFFAOYSA-N 0.000 description 1
- TXHAHOVNFDVCCC-UHFFFAOYSA-N 2-(tert-butylazaniumyl)acetate Chemical compound CC(C)(C)NCC(O)=O TXHAHOVNFDVCCC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- FRJIAZKQGSCKPQ-FSPLSTOPSA-N His-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1 FRJIAZKQGSCKPQ-FSPLSTOPSA-N 0.000 description 1
- LYCVKHSJGDMDLM-LURJTMIESA-N His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 LYCVKHSJGDMDLM-LURJTMIESA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000004472 Lysine Chemical group 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035554 Proglucagon Human genes 0.000 description 1
- 108010058003 Proglucagon Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical group OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 description 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 1
- 108010040030 histidinoalanine Proteins 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 238000012528 insulin ELISA Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 235000021231 nutrient uptake Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a derivative of the insulin secretion peptides modified to have increased insulin secretion activity and hypoglycemic activity and a pharmaceutical composition comprising the same, wherein the insulin secretion peptide derivative according to the invention is characterized in that the N-terminal charge of the insulin secretion peptide It is characterized by being modified to have a neutral or net negative charge.
- Peptides generally have low stability, are easily denatured, degraded by proteolytic enzymes in the body, and lose their activity. Also, since peptides are relatively small and easily removed through the kidneys, peptides containing pharmacologically active peptides in the blood Peptide drugs need to be frequently administered to patients to maintain concentrations and titers.
- Peptide drugs are mostly administered to patients in the form of injectables, so that frequent injections are required to maintain blood levels of bioactive peptides, which causes tremendous pain in the patient.
- efforts are being actively made to maximize the drug efficacy by increasing the blood stability of the peptide drug and maintaining the blood drug concentration for a long time.
- long-acting formulations of such peptide drugs should increase the stability of the peptide drug while keeping the titer of the drug itself high enough and not elicit an immune response in the patient. Accordingly, there have been attempts to alter specific amino acid sequences sensitive to proteolytic enzymes as a method for stabilizing peptide drugs and inhibiting degradation by proteolytic enzymes.
- GLP-1 (7-37 or 7-36 amide), which acts to reduce blood glucose levels and is effective in treating type 2 diabetes, has a very short bioactive half-life of less than 4 minutes, which is dipep It is due to the loss of titer of GLP-1 by cleavage between the 8th (Ala) and 9th (Asp) amino acids of GLP-1 by thidyl pepdidase IV (DPP IV). Accordingly, a GLP-1 derivative has been developed that maintains physiological activity while increasing resistance to DPP IV by substituting Ala 8 of GLP-1 with Gly, Leu or D-Ala.
- the N-terminal amino acid His 7 of GLP-1 is also very important for the activity of GLP-1 and at the same time is a target of DPP IV.
- the N-terminus was modified with an alkyl or acyl group, or His 7 was N-methylated or alpha-methylated to increase DPP IV resistance and maintain physiological activity.
- the receptor affinity of the derivatives modified with His 7 was significantly decreased, and the problem of decreasing the secretion ability of cAMP at the same concentration was reported (Gallwitz et al. , Regulatory Peptide 79: 93-102, 1999; Gallwitz et al., Regulatory Peptide 86: 103-111, 2000).
- exendin-4 is composed of His-Gly rather than His-Ala, which is a sequence of GLP-1 serving as a substrate of DPP IV. It has a physiological activity higher than -1 and thus has a longer half-life in the body than GLP-1.
- exendin-4 (exenatide, exenatide) should be administered twice daily to the patient, which is still a significant burden on the patient. It can not be.
- the inventors have made intensive efforts to increase the activity and blood stability of the insulin secreting peptides, and as a result, derivatives that have modified the charge of the N-terminal amino acids of the insulin secreting peptides have superior pharmacokinetics and higher
- the present invention has been completed by confirming that it exhibits insulin secretion activity.
- Another object of the present invention to provide a pharmaceutical composition for treating diabetes containing the insulin secretion peptide derivative as an active ingredient.
- Still another object of the present invention is to provide a method for treating diabetes using the insulin secreting peptide derivative.
- the present invention provides an insulin secreting peptide derivative in which the N-terminal charge of the insulin secreting peptide is modified.
- the present invention provides insulin secretory peptide derivatives wherein the N-terminal amino group or amino acid residues of the insulin secreting peptide have been modified to have either a neutral charge or a net negative charge.
- the insulin secreting peptide derivative according to the present invention is chemically modified to have a neutral or net negative charge by removing or replacing the alpha-amino group of the N-terminal histidine residue of the insulin secreting peptide, or by removing the alpha-carbon. It is characterized by a modification.
- the insulin secreting peptide derivative according to the present invention is freed from the N-terminal amino group of the insulin secreting peptide; Replacing the N-terminal amino group with a hydroxyl group; Modifying the N-terminal amino group with two methyl residues; Replacing the N-terminal amino group with a carboxyl group; Removing the alpha carbon of the N-terminal histidine residue leaving only the imidazoleacetyl residue; The N-terminal amino group is removed and a chemical modification corresponding to at least one of the C-terminal carboxyl groups substituted with propylamide is introduced.
- the insulin secreting peptide derivative according to the present invention is a N-terminal histidine residue of the insulin secreting peptide wherein the des-amino-histidyl, dimethyl-histidyl, beta-hydroxy imidazopropionyl, 4 -Is substituted with a material selected from the group consisting of imidazoacetyl and beta-carboxy imidazopropionyl.
- the insulin secreting peptide derivative according to the present invention has N-terminal histidine residues of insulin secreting peptides substituted with des-amino-histidyl, and C-terminal carboxyl groups are substituted with propylamide. Characterized in that substituted.
- the insulin secreting peptide in the insulin secreting peptide derivative according to the present invention is characterized by having a binding ability to the GLP-1 receptor.
- the insulin secreting peptide in the insulin secreting peptide derivative according to the present invention is represented by GLP-1 represented by SEQ ID NO: 1, exendin-4 represented by SEQ ID NO: 2, and SEQ ID NO: 3
- GLP-1 represented by SEQ ID NO: 1
- exendin-4 represented by SEQ ID NO: 2
- SEQ ID NO: 3 To be exendin-3, an auxintomodulin represented by SEQ ID NO: 5, a GIP represented by SEQ ID NO: 6, or an analog thereof.
- the insulin secreting peptide derivative according to the invention has an increased dissociation constant (Kd) relative to the native insulin secreting peptide for the GLP-1 receptor due to the modification of the N-terminal charge do.
- the insulin secreting peptide derivative according to the present invention is a N-terminal histidine residue of GLP-1, exendin-4, exendin-3, oxyntomodulin, GIP or an analog thereof. -Substituted by histidyl, dimethyl-histidyl, beta-hydroxy imidazopropionyl, 4-imidazoacetyl or beta-carboxy imidazopropionyl.
- the insulin secreting peptide derivative according to the present invention is a N-terminal histidine residue of GLP-1, exendin-4, exendin-3, oxyntomodulin, GIP or an analog thereof is des-amino. -Is substituted with histidyl, and the C-terminal carboxyl group is substituted with propylamide.
- the insulin secreting peptide derivative according to the present invention comprises desamino-histidyl-exendin-4, wherein the N-terminal amino group of exendin-4 is removed; Beta-hydroxy imidazopropionyl-exendin-4 in which the N-terminal amino group of exendin-4 is substituted with a hydroxyl group; Beta-carboxyimidazopropyl-exendin-4 in which the N-terminal amino group of exendin-4 is substituted with a carboxyl group; Dimethyl-histidyl-exendin-4 wherein the N-terminal amino group of exendin-4 is modified with two methyl residues; And imidazoacetyl-exendin-4 from which alpha carbon of histidine, which is the first amino acid of exendin-4, has been removed.
- the insulin secreting peptide derivative according to the present invention removes the N-terminal amino group of exendin-4 and the DA-exendin-4- with its C-terminal carboxyl group substituted with propylamide. It is characterized in that the propyl-amide (DA-Exendin-4-propyl-amide).
- the present invention provides a pharmaceutical composition for treating diabetes comprising the N-terminal charge-modified insulin secreting peptide derivative as described above as an active ingredient.
- the invention provides a method of treating diabetes in a subject comprising administering to the subject in need thereof a therapeutically effective amount of an N-terminal charge modified insulin secreting peptide derivative as described above. do.
- N-terminal charge-modified insulin secreting peptide derivatives according to the present invention can be rapidly dissociated from the GLP-1 receptor to prevent clearance of the insulin secreting peptide by the receptor and to cause less desensitization. can do.
- the insulin secretion peptide derivatives of which the N-terminal charge is modified according to the present invention have increased insulin secretion activity and in vivo blood glucose lowering in comparison with the native insulin secretion peptides due to the above-described changes in binding capacity to the GLP-1 receptor. It can be very useful for treating diabetes.
- Figures 1a to 1d shows the concentration-specific binding curve of the N-terminal charge-modified insulin secretion peptide derivatives according to the present invention to the GLP-1 receptor
- Figure 1a is a natural type exendin-4
- Figure 1b is CA- Exendin-4
- FIG. 1C shows DA-Exendin-4
- FIG. 1D shows DA-Exendin-4-propyl-amide
- FIG. 1E shows HY-Exendin-4.
- Figure 2 is a result of measuring the insulin secretion activity of the natural type exendin-4 and the N-terminal charge modified CA- exendin-4 derivatives according to the present invention.
- Figure 3 is a result of measuring the blood glucose lowering ability of the natural type exendin-4 and the N-terminal charge modified CA- exendin-4 derivatives according to the present invention in a diabetic model animal.
- the present invention relates to insulin secreted peptide derivatives with modified N-terminal charges of the insulin secreted peptide.
- the insulin secreting peptide derivative according to the present invention is characterized by changing the N-terminal charge of the insulin secreting peptide to cause rapid dissociation with the receptor.
- insulin secreting peptide derivative refers to the neutral or net negative charge of the N-terminal charge of a naturally occurring insulin secreting peptide, analog or fragment thereof, by means of chemical, genetic or physical manipulation, while possessing intrinsic insulin secretion function. Refers to a modified to have.
- the insulin secreting peptide derivative according to the present invention is preferably chemically modified such that the N-terminal amino group or amino acid residue of the insulin secreting peptide at neutral pH has a neutral or net negative charge. More preferably, the derivative of which the positive charge of the first amino acid residue at the N-terminus of the insulin secreting peptide according to the invention is modified to a neutral or net negative charge.
- insulin secreting peptide in the present invention is a peptide having insulin secretory function, which stimulates the synthesis and expression of insulin of pancreatic beta cells.
- Insulin secreting peptides suitable for the present invention can be used as long as they are capable of binding to the GLP-1 receptor and exhibit physiological activity.
- GLP-1 (7-37), SEQ ID NO: Exendin-4 of SEQ ID NO: 2, exendin-3 of SEQ ID NO: 3, oxyntomodulin of SEQ ID NO: 5, glucose-dependent insulinotropic polypeptide of SEQ ID NO: 6, GIP), analogs or fragments thereof.
- analogue of insulin secreting peptide refers to a peptide having insulin secretion function as a peptide having one or more amino acid sequences different from the native insulin secreting peptide.
- analogues of the insulin secreting peptides according to the invention refer to polypeptides that show homology in an amino acid sequence of at least 80% or more as compared to the native insulin secreting peptide, wherein some groups of amino acid residues are chemically substituted (eg : alpha-methylation, alpha-hydroxylation), removed (eg deamination) or modified (eg N-methylation).
- analogs of the insulin secreting peptides mean that the insulin secreting function exhibits equal or more compared to the native insulin secreting peptides, but the extent of analogs of the insulin secreting peptides according to the invention is necessarily to this extent. It is not limited to those with levels of insulin secretion.
- fragment of insulin secreting peptide refers to a form in which one or more amino acids are added or deleted at the N-terminus or C-terminus of a native insulin secreting peptide while retaining insulin secreting function. Amino acids that do not exist in nature (eg D-type amino acids) are possible.
- GLP-1 is a hormone secreted by the small intestine, which generally promotes insulin biosynthesis and secretion, inhibits glucagon secretion and promotes cellular uptake of glucose.
- the glucagon precursor is broken down into three peptides: glucagon, GLP-1 and GLP-2.
- GLP-1 means GLP-1 (1 to 37), and has no insulin secretion function, and is processed to form GLP-1 (7-37) to become active GLP-1 (7-37).
- GLP-1 (7-37) has an amino acid sequence represented by SEQ ID NO: 2.
- the GLP-1 analog is Arg 34 -GLP-1 (7-37), Gly 8 -GLP-1 (7-36) -amide, Gly 8 -GLP-1 (7-37), Val 8- GLP-1 (7-36) -amide, Val 8 -GLP-1 (7-37), Val 8 Asp 22 -GLP-1 (7-36) -amide, Val 8 Asp 22 -GLP-1 (7- 37), Val 8 Glu 22 -GLP-1 (7-36) -amide, Val 8 Glu 22 -GLP-1 (7-37), Val 8 Lys 22 -GLP-1 (7-36) -amide, Val 8 Lys 22 -GLP-1 (7-37), Val 8 Arg 22 -GLP-1 (7-36) -amide, Val 8 Arg 22 -GLP-1 (7-37), Val 8 His 22 -GLP- 1 (7-36) -amide, Val 8 His 22 -GLP-1 (7-37), Val 8 Trp 16 Glu 22 -GLP-1 (7-37), Val 8 Trp 16 Glu
- exendin-4 is a polypeptide of 39 amino acids showing 53% amino acid sequence similarity with GLP-1, having the amino acid sequence represented by SEQ ID NO: 2.
- Exendin-3 has an amino acid sequence represented by SEQ ID NO: 3, which is an exendin-4 analog that differs only from exendin-4 and amino acids 2 and 3.
- Exendin-3 may be represented by Ser 2 Asp 3 -exendin-4 (1-39) in which amino acids at positions 2 and 3 of exendin-4 are substituted with serine and aspartic acid, respectively.
- ZP-10 As another exendin-4 analog, ZP-10, wherein the amino acids at positions 38 and 39 of exendin-4 are substituted with serine and lysine, respectively, is Ser 38 Lys 39 -Exendin-4 (1-39) -LysLysLysLysLys-. It is represented by an amide and has the amino acid sequence of SEQ ID NO: 4.
- Oxintomodulin is a peptide made from pre-glucagon, a precursor of glucagon, and is released from L-cells of the small intestine in proportion to nutrient intake with GLP-1.
- Oxintomodulin is a peptide hormone consisting of 37 amino acids represented by SEQ ID NO: 5, which inhibits food intake, enhances satiety, and shows the lipolytic function of glucagon.
- Glucose-dependent insulin secreting polypeptide is an incretin that regulates the secretion of insulin in the pancreas in response to glucose concentration in response to intestinal nutrient uptake, consisting of 42 amino acids set forth in SEQ ID NO: 6 and intestine Is secreted from K cells. GIP not only stimulates glucose secretion in beta cells but also promotes insulin synthesis, induces beta cell proliferation, and has an inhibitory effect on death.
- insulin secreting peptides that differ in one or more amino acid sequences and are deaminated to N-terminal amino acid residues are also included.
- the natural insulin secreting peptides and modified insulin secreting peptide derivatives used in the present invention can be synthesized through solid phase synthesis, and most natural polypeptides including natural insulin secreting peptides are recombinant. It can also be produced.
- the GLP-1, Exendin-4, Exendin-3, Oxintomodulin, or analog of GIP may be substituted, deleted, and / or substituted with one or more amino acids of native GLP-1, Exendin-4, or Exendin-3.
- the insulin secreting peptide derivative according to the invention is characterized in that the N-terminal amino group or amino acid residue of the native insulin secreting peptide, analog or fragment thereof, is modified to have a neutral or net negative charge.
- the insulin secreting peptide derivative according to the present invention is a derivative chemically modified such that the positive charge of the N-terminal first amino acid residue of the insulin secreting peptide has a neutral or net negative charge.
- the insulin secreting peptide derivative according to the present invention wherein the N-terminus is modified to have a neutral or net negative charge, is characterized by having a higher dissociation constant (Kd) for the GLP-1 receptor as compared to the native insulin secreting peptide.
- Kd dissociation constant
- the insulin secreting peptide derivative according to the present invention has a dissociation constant for the GLP-1 receptor that is increased by at least 2 times, more preferably at least 3 times and most preferably at least 6 times compared to the native insulin secreting peptide. Modified to have Kd), but is not limited thereto.
- Insulin secreted peptide derivatives according to the invention wherein the N-terminal positive charge of the insulin secreting peptide is modified to neutral or net negative charge can be prepared by a variety of methods known in the art, and preferably N of the insulin secreting peptide having a positive charge. It can be modified to have a neutral or net negative charge by removing or replacing the alpha-amino group of the terminal histidine residue or by removing the alpha-carbon.
- the N-terminal charge-modified insulin secreting peptide derivative according to the present invention includes a derivative in which the N-terminal amino group of the insulin secreting peptide is removed (desamino-histidyl derivative); A derivative in which its N-terminal amino group is substituted with a hydroxyl group (beta-hydroxy imidazopropionyl-derivative); Derivatives in which the N-terminal amino group thereof is modified with two methyl residues (dimethyl-histidyl-derivative); A derivative in which its N-terminal amino group is substituted with a carboxyl group (beta-carboxy imidazopropionyl-derivative); The imidazoacetyl-derivative may be included by removing the alpha carbon of its N-terminal histidine residue, leaving only the imidazoacetyl group, and may be modified as long as the N-terminal positive charge can be transformed into a neutral or net negative charge.
- N-terminal charge-modified insulin secreting peptide derivative may be represented by the following structural formula.
- the C-terminal carboxyl group of the desamino-histidyl-derivative having the N-terminal amino group removed is substituted with propylamide.
- Derivatives may be included.
- N-terminal charge-modified insulin secreting peptide derivative may be represented by the following structural formula.
- the insulin secreting peptide derivative according to the invention N-terminal histidine residues of GLP-1, exendin-4, exendin-3, auxintomodulin, GIP, analogs or fragments thereof are des-amino-histidyl, dimethyl-histidyl, beta-hydroxy imide
- the charge at the N-terminus may be modified by substitution with dazopropionyl, 4-imidazoacetyl or beta-carboxy imidazopropionyl.
- the N-terminal charge modified insulin secretion peptide derivative according to the invention can be represented by the following formula (1).
- R 1 is selected from the group consisting of des-amino-histidyl, dimethyl-histidyl, beta-hydroxy imidazopropionyl, 4-imidazoacetyl and beta-carboxy imidazopropionyl,
- R 2 is —NH 2 or —OH
- X is Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ila Ala Trp Leu Val Lys Gly Arg Gly;
- the insulin secreting peptide derivative is a derivative in which the N-terminal charge of exendin-4 is modified, and desamino-histidyl-exendin-4 from which the N-terminal amino group of exendin-4 is removed.
- insulin secreting peptide derivative according to the present invention is a N-terminal histidine residue of GLP-1, exendin-4, exendin-3, auxintomodulin, GIP, an analog or fragment thereof is des-amino-histidyl Substituted and its C-terminal carboxyl group may be substituted with propylamide.
- the N-terminal charge-modified insulin secreting peptide derivative comprises desamino-histidyl-exendin-4 (DA-exendin-4) wherein the N-terminal amino group of exendin-4 has been removed.
- the derivatives are those that remove or substitute the alpha-amino group of the amino-terminal histidine residue or remove the alpha-carbon, and the other amino acid sequences are not particularly limited as long as the physiological activity is maintained.
- Modification of the N-terminal positive charge to a neutral or net negative charge in the insulin secreting peptide derivative of the present invention can induce dissociation with the GLP-1 receptor to prevent clearance of the insulin secreting peptide by the receptor. This may lead to less desensitization, leading to superior physiological activity.
- the insulin secreting peptide derivative according to the present invention increases the insulin secretion activity compared to the natural insulin secreting peptide due to the change in the binding capacity to the GLP-1 receptor due to the change in the N-terminal charge of the insulin secreting peptide neutral or net positive charge In addition, it can exhibit excellent blood glucose lowering ability in vivo .
- insulin secreting peptide derivatives in which the positive charge of the N-terminal amino acid of the insulin secreting peptide is neutral or net negatively charged has a higher dissociation constant (Kd) than the native insulin secreting peptide for the GLP-1 receptor. It was confirmed that this can repeat the frequent binding / dissociation with the GLP-1 receptor (see Example 1).
- the N-terminal charge-modified insulin secreting peptide derivative exhibited about two-fold increased insulin secretion activity compared to the native-type insulin secreting peptide with no charge-modifying (see Example 2).
- (db / db mice) showed about 5-fold increased blood glucose lowering ability compared to the native insulin secreting peptide (see Example 3).
- the insulin secreting peptide derivative according to the present invention in which the N-terminal charge of the insulin secreting peptide is modified, increases the dissociation constant for the GLP-1 receptor, that is, increases the dissociation from the GLP-1 receptor, resulting in excellent blood stability and insulin. It can be seen that the secretory ability.
- altering the N-terminal charge of an insulin secreting peptide to a neutral or net negative charge can increase the binding capacity of the GLP-1 receptor, especially dissociation from the receptor, thereby increasing the biological activity of the insulin secreting peptide.
- This is the first fact identified in the present invention. Therefore, the excellent blood stability and insulin secretion activity of the insulin secreting peptide derivative according to the present invention will be useful for maximizing the effect of type 2 diabetes treatment.
- the present invention provides a pharmaceutical composition for treating diabetes, which contains, as an active ingredient, a modified insulin secreting peptide derivative at the N-terminus of an insulin secreting peptide.
- N-terminal charge modified insulin secreting peptide derivative is as described above.
- N-terminal charge-modified insulin secretion peptide derivative according to the present invention has a high insulin secretion activity and blood glucose lowering ability compared to the natural insulin secretion peptide, it can be used as an excellent diabetes treatment.
- the pharmaceutical composition for treating diabetes of the present invention can effectively treat diabetes by administering to a subject in need thereof.
- the scope of the present invention includes methods of treating diabetes in a subject comprising administering to a subject in need thereof a therapeutically effective amount of an N-terminal charge modified insulin secreting peptide derivative as described above. .
- treatment means any action in which the symptoms of diabetes improve or benefit altered by administration of an N-terminal charge-modified insulin secreting peptide derivative or a pharmaceutical composition comprising the same.
- the term “administration” means introducing any substance to a subject, i.e., an N-terminal charge modified insulin secreting peptide derivative or a pharmaceutical composition comprising the same, in any suitable manner, Its route of administration can be administered via any general route so long as the drug can reach the target tissue.
- the route of administration may be, but is not limited to, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, pulmonary administration, rectal administration, and the like.
- the oral composition is preferably formulated to coat the active agent or to protect it from degradation in the stomach. It may preferably be administered in the form of an injection.
- the pharmaceutical composition may be administered by any device that allows the active substance to migrate to the target cell.
- compositions comprising derivatives of the invention may comprise a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers may be used as oral administration binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, pigments, flavoring agents, etc., in the case of injections, buffers, preservatives , A non-solvent, solubilizer, isotonic agent, stabilizer and the like can be used in combination.
- bases, excipients, lubricants, preservatives and the like can be used for topical administration.
- the formulation of the pharmaceutical composition of the present invention can be prepared in various ways by mixing with the pharmaceutically acceptable carrier as described above.
- oral administration in the case of oral administration, it may be prepared in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc., and in the case of injections, they may be prepared in unit dosage ampoules or multiple dosage forms. . It may be formulated into other solutions, suspensions, tablets, pills, capsules, sustained release preparations and the like.
- suitable carriers, excipients and diluents suitable for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl Cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil and the like can be used.
- fillers, anti-coagulants, lubricants, wetting agents, fragrances, preservatives and the like may be further included.
- the N-terminal charge modified insulin secreting peptide derivative or the pharmaceutical composition comprising the same according to the present invention is administered in a therapeutically effective amount.
- therapeutically effective amount refers to an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level is determined by the type of disease, the severity, the activity of the drug, the drug. Sensitivity, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of drugs, and other factors well known in the medical arts.
- the N-terminal charge-modified insulin secreting peptide derivative or the pharmaceutical composition comprising the same according to the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, which can be easily determined by those skilled in the art.
- the dosage and frequency of the pharmaceutical composition of the present invention is determined according to the type of drug which is the active ingredient, along with various related factors such as the disease to be treated, the route of administration, the age, sex and weight of the patient and the severity of the disease. Since the pharmaceutical composition of the present invention has excellent persistence and titer in vivo, the frequency and frequency of administration of the pharmaceutical preparations according to the present invention can be significantly reduced.
- subject means an animal including, but not limited to, humans, monkeys, cows, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, rats, axes or guinea pigs, In one embodiment it refers to a mammal and in another embodiment a human.
- the binding capacity of the GLP-1 receptor and the insulin secreting peptide derivative with the N-terminal charges modified was measured using a surface plasmon resonance (SPR) device (BIACORE 3000, GE Healthcare).
- SPR surface plasmon resonance
- N-terminal charge-modified insulin secreting peptide derivatives CA-Exendin-4 (CA-Exendin-4), DA-Exendin-4 (DA-Exendin-4), HY-Exendin-4 (HY -Exendin-4) and DA-Exendin-4-propyl-amide were used.
- CA-Exendin-4 is a derivative obtained by removing the alpha carbon of the N-terminal histidine residue of Exendin-4; DA-exendin-4 is a derivative from which the N-terminal amino group of exendin-4 is removed; HY-Exendin-4 is a derivative in which the N-terminal amino group of Exendin-4 is substituted with a hydroxyl group; DA-exendin-4-propyl-amide is a derivative in which the N-terminal amino group of exendin-4 is removed and the C-terminal carboxyl group is substituted with propylamide.
- a natural type exendin-4 (exenatide: Byetta) was used as a control.
- Exendin-4 derivatives with modified N-terminal charges were synthesized by American Peptide Corporation, and native exendin-4 was obtained from Amylin Pharmaceuticals.
- the GLP-1 receptor was expressed in hGLP-1R / GST form in CHO-DG44 cells and the expressed hGLP-1R / GST was immobilized on the CM5 chip by amine coupling.
- the N-terminal charge-modified insulin secreting peptide derivative was diluted and added to the CM5 chip immobilized with hGLP-1R / GST to measure binding ability with the GLP-1 receptor.
- the binding force between the N-terminal charge-modified insulin secreting peptide derivative and the GLP-1 receptor was analyzed according to a 1: 1 Langmuir fitting model, and the results are shown in FIGS. 1A to 1E and Table 1 below. Indicated.
- the N-terminus of the native exendin-4 has a positive charge
- the exendin-4 derivatives whose charge is modified to a neutral charge are native exendin-4. It was found to have a significantly higher dissociation constant (kd). The results indicate that more frequent binding / dissociation may occur repeatedly between the GLP-1 receptor and the insulin secreting peptide derivative with the N-terminal charge modified.
- Such pharmacokinetic changes on the GLP-1 receptor can prevent the clearance of insulin secreting peptide derivatives by the receptor and make desensitization less favorable for increased blood stability.
- the insulin secretion activity of the exendin-4 derivatives modified with N-terminal charge was compared in RINm5F cells. After thawing, RINm5F cells passaged at least once were inoculated with a culture medium containing FBS (Gibco, # 11082) to 1 ⁇ 10 5 cells / well in a 96-well plate and 48 hours in a 37 ° C., 5% CO 2 incubator. Incubated for To measure insulin secretion activity, the culture medium of cultured RINm5F cells was exchanged with culture medium containing 0.5% FBS and further cultured for 1 hour.
- FBS Gibco, # 11082
- N-terminal charge-modified insulin secreting peptide derivative and native exendin-4 (exenatide: Byetta) as in Example 1 were diluted with culture medium containing 0.5% FBS and glucose, respectively, at 10 nM to 0.001 nM Prepared until. At this time, a culture medium containing no exendin-4 was used as a control. After removing all of the cultured RINm5F cells and adding the prepared samples, the cells were incubated in a 37 ° C., 5% CO 2 incubator for 1 hour, and then all of the wells were recovered. Insulin concentration of the recovered medium was measured using a rat insulin ELISA kit (Mercodia), and the results are shown in FIG. 2 and Table 2 below.
- the N-terminal charge-modified insulin secretion peptide derivative according to the present invention was found to exhibit about 1.25 times better insulin secretion activity than the native type exendin-4 in the same concentration range It became.
- Example 3 Comparison of in vivo activity of insulin secreted peptide derivatives with modified N-terminal charges
- N-terminal charge modified insulin secreting peptide derivatives In order to measure the in vivo activity of N-terminal charge modified insulin secreting peptide derivatives, their hypoglycemic ability in diabetic model animals was compared with native exendin-4. After fasting db / db mice (Jackson Lab, 10-12 weeks of age) for 2 hours, insulin secreting peptides modified with 0.01-1000 mcg / kg native exendin-4 (exenatide: Byetta) and N-terminal charges The derivatives were each administered via the subcutaneous route. At this time, the vehicle was administered in the same manner (vehicle), the blood glucose change according to the administered drug at each dose concentration was calculated as the percentage change value compared to the vehicle.
- N-terminal charge-modified insulin secretion peptide derivative according to the present invention showed about 5 times increased blood glucose lowering ability than native type exendin-4 .
- the N-terminal charge-modified insulin secreting peptide derivative according to the present invention has a faster dissociation from the GLP-1 receptor due to the increased dissociation constant for the GLP-1 receptor, which is superior to the native insulin secreting peptide. It can be seen that the present invention shows stability in blood and thus increased insulin secretion ability and hypoglycemic activity. Therefore, the insulin secreting peptide derivative according to the present invention can be very useful for the treatment of type 2 diabetes.
- N-terminal charge-modified insulin secreting peptide derivatives according to the present invention can be rapidly dissociated from the GLP-1 receptor to prevent clearance of the insulin secreting peptide by the receptor and to cause less desensitization. can do.
- the insulin secretion peptide derivatives of which the N-terminal charge is modified according to the present invention have increased insulin secretion activity and in vivo blood glucose lowering compared to the native insulin secretion peptides due to the above-described changes in binding capacity to the GLP-1 receptor. It can be very useful for treating diabetes.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
시료 | pH 7.4에서 N-말단 전하 | ka(1/Ms, ×105) | kd(1/s, ×104) | KD(nM) |
천연형 엑센딘-4 | 양전하 | 3.70±0.06 | 5.26±0.11 | 1.4±0.05 |
CA-엑센딘-4 | 중성 전하 | 1.20±0.11 | 31.5±0.56 | 26.3±2.08 |
DA-엑센딘-4 | 1.13±0.08 | 36.5±1.40 | 32.2±1.89 | |
DA-엑센딘-4-프로필-아미드 | 1.04±0.11 | 33.5±1.40 | 32.6±4.17 | |
HY-엑센딘-4 | 0.90±0.07 | 38.3±1.92 | 42.7±4.10 |
시료 | 대조군 대비 최대 인슐린 분비량의 비율 |
N-말단 전하가 변형된 인슐린 분비 펩티드 유도체 | 198.9 % |
천연형 엑센딘-4 | 159.0 % |
시료 | ED50(mcg/kg) | R2 |
N-말단 전하가 변형된 인슐린 분비 펩티드 유도체 | 2.30 | 0.99 |
천연형 엑센딘-4 | 9.92 | 0.98 |
Claims (17)
- 인슐린 분비 펩티드 유도체로서, 상기 유도체가 천연형 인슐린 분비 펩티드의 N-말단 전하(charge)에 변형이 있는, 인슐린 분비 펩티드 유도체.
- 제1항에 있어서, 상기 인슐린 분비 펩티드 유도체가 천연형 인슐린 분비 펩티드, 그 유사체 또는 단편의 N-말단 아미노 그룹 또는 아미노산 잔기의 양전하가 중성 또는 알짜 음전하를 갖도록 화학적으로 변형된 것인, 인슐린 분비 펩티드 유도체.
- 제2항에 있어서, 상기 천연형 인슐린 분비 펩티드, 그 유사체 또는 단편은 그의 N-말단 잔기가 히스티딘이고, 상기 변형은 상기 히스티딘 잔기의 알파-아미노 그룹을 제거 또는 치환하거나, 알파-카본을 제거함으로써 중성 또는 알짜 음전하를 갖도록 한 변형인 것인, 인슐린 분비 펩티드 유도체.
- 제3항에 있어서, 상기 변형은 천연형 인슐린 분비 펩티드, 그 유사체 또는 단편의 N-말단 아미노 그룹이 제거되고; 상기 N-말단 아미노 그룹을 히드록실 그룹으로 치환하고; 상기 N-말단 아미노 그룹을 2개의 메틸 잔기로 수식하고; 상기 N-말단 아미노 그룹을 카르복실 그룹으로 치환하고; 상기 N-말단 히스티딘 잔기의 알파 카본을 제거하여 이미다졸아세틸 잔기만을 남겨두거나; 상기 N-말단 아미노 그룹을 제거하고 C-말단의 카르복실 그룹을 프로필아미드(propylamide)로 치환하는 것 중의 하나 이상을 포함하는 것인, 인슐린 분비 펩티드 유도체.
- 제4항에 있어서, 상기 인슐린 분비 펩티드 유도체는 천연형 인슐린 분비 펩티드, 그 유사체 또는 단편의 N-말단 잔기가 데스-아미노-히스티딜, 다이메틸-히스티딜, 베타-히드록시 이미다조프로피오닐, 4-이미다조아세틸 및 베타-카르복시 이미다조프로피오닐로 구성되는 군에서 선택되는 물질로 치환된 것인, 인슐린 분비 펩티드 유도체.
- 제4항에 있어서, 상기 인슐린 분비 펩티드 유도체는 천연형 인슐린 분비 펩티드, 그 유사체 또는 단편의 N-말단 잔기가 데스-아미노-히스티딜로 치환되고, C-말단 카르복실 그룹이 프로필아미드로 치환된 것인, 인슐린 분비 펩티드 유도체.
- 제1항에 있어서, 상기 인슐린 분비 펩티드 유도체가 GLP-1 수용체에 대한 결합 활성을 갖는 것인, 인슐린 분비 펩티드 유도체.
- 제1항에 있어서, 상기 천연형 인슐린 분비 펩티드가 서열번호: 1로 표시되는 GLP-1, 서열번호: 2로 표시되는 엑센딘-4, 서열번호: 3으로 표시되는 엑센딘-3, 서열번호: 5로 표시되는 옥신토모듈린, 서열번호: 6으로 표시되는 GIP, 이들의 유사체 또는 단편인 것인, 인슐린 분비 펩티드 유도체.
- 제8항에 있어서, 상기 천연형 인슐린 분비 펩티드 또는 그의 유사체가 GLP-1 유사체이고, Arg34-GLP-1(7-37), Gly8-GLP-1(7-36)-아미드, Gly8-GLP-1(7-37), Val8-GLP-1(7-36)-아미드, Val8-GLP-1(7-37), Val8Asp22-GLP-1(7-36)-아미드, Val8Asp22-GLP-1(7-37), Val8Glu22-GLP-1(7-36)-아미드, Val8Glu22-GLP-1(7-37), Val8Lys22-GLP-1(7-36)-아미드, Val8Lys22-GLP-1(7-37), Val8Arg22-GLP-1(7-36)-아미드, Val8Arg22-GLP-1(7-37), Val8His22-GLP-1(7-36)-아미드, Val8His22-GLP-1(7-37), Val8Trp16Glu22-GLP-1(7-37), Val8Glu22Val25-GLP-1(7-37), Val8Tyr16Glu22-GLP-1(7-37), Val8Trp16Glu22-GLP-1(7-37), Val8Leu16Glu22-GLP-1(7-37), Val8Tyr18Glu22-GLP-1(7-37), Val8Glu22His37-GLP-1(7-37), Val8Glu22,Il33-GLP-1(7-37), Val8Trp16Glu22Val25Ile33-GLP-1(7-37), Val8Trp16Glu22Ile33-GLP-1(7-37), Val8Glu22Val25Ile33-GLP-1(7-37), 및 Val8Trp16Glu22Val25-GLP-1(7-37)로 구성된 군으로부터 선택되는 것인, 인슐린 분비 펩티드 유도체.
- 제8항에 있어서, 상기 천연형 인슐린 분비 펩티드 또는 그의 유사체가 서열번호: 4의 ZP-10(Ser38Lys39-엑센딘-4(1~39)-LysLysLysLysLys-아미드) 엑센딘-4 유사체인, 인슐린 분비 펩티드 유도체.
- 제1항에 있어서, 상기 인슐린 분비 펩티드 유도체가 그의 천연형 인슐린 분비 펩티드와 비교하여 GLP-1 수용체에 대해 더 큰 해리 상수(Kd)를 갖는 것인, 인슐린 분비 펩티드 유도체.
- 제5항에 있어서, 상기 인슐린 분비 펩티드 유도체가 하기 화학식 1로 표시되는 것인, 인슐린 분비 펩티드 유도체:R1-X-R2 <화학식 1>상기 식에서, R1은 데스-아미노-히스티딜, 다이메틸-히스티딜, 베타-히드록시 이미다조프로피오닐, 4-이미다조아세틸 및 베타-카르복시 이미다조프로피오닐로 구성되는 군으로부터 선택되고,R2는 -NH2 또는 -OH이고,X는 Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly;Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser;Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser; 또는Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn Arg Asn Asn Ile Ala임.
- 제6항에 있어서, 상기 인슐린 분비 펩티드 유도체가 GLP-1, 엑센딘-4, 엑센딘-3, 옥신토모듈린, GIP 또는 이의 유사체의 N-말단 히스티딘 잔기가 데스-아미노-히스티딜로 치환되고, C-말단 카르복실 그룹이 프로필아미드로 치환된 것인, 인슐린 분비 펩티드 유도체.
- 제12항에 있어서, 상기 인슐린 분비 펩티드 유도체가 엑센딘-4의 N-말단 아미노 그룹을 제거한 데스아미노-히스티딜-엑센딘-4(desamino-histidyl-exendin-4); 엑센딘-4의 N-말단 아미노 그룹을 히드록실 그룹으로 치환한 베타-히드록시 이미다조프로피오닐-엑센딘-4(beta-hydroxy imidazopropionyl-exendin-4); 엑센딘-4의 N-말단 아미노 그룹을 카르복실 그룹으로 치환한 베타-카르복시 이미다조프로필-엑센딘-4(beta-carboxyimidazopropionyl-exendin-4); 엑센딘-4의 N-말단 아미노 그룹을 2개의 메틸 잔기로 수식한 다이메틸-히스티딜-엑센딘-4 (dimethyl-histidyl-exendin-4); 및 엑센딘-4의 첫 번째 아미노산인 히스티딘의 알파 탄소를 제거한 이미다조아세틸-엑센딘-4(imidazoacetyl-exendin-4)로 구성된 군으로부터 선택되는 것인, 인슐린 분비 펩티드 유도체.
- 제13항에 있어서, 상기 인슐린 분비 펩티드 유도체가 엑센딘-4의 N-말단 아미노 그룹을 제거하고 그의 C-말단 카르복실 그룹이 프로필아미드로 치환된 DA-엑센딘-4-프로필-아미드(DA-Exendin-4-propyl-amide)인 것인, 인슐린 분비 펩티드 유도체.
- 제1항 내지 제15항 중 어느 한 항에 따른 인슐린 분비 펩티드 유도체를 유효성분으로 함유하는 당뇨병 치료용 약학적 조성물.
- 제1항 내지 제15항 중 어느 한 항에 따른 인슐린 분비 펩티드 유도체를 이를 필요로 하는 대상에게 치료학적 유효량으로 투여하는 것을 포함하는, 대상에게서 당뇨병을 치료하는 방법.
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/758,842 US9663565B2 (en) | 2013-01-03 | 2014-01-03 | Insulinotropic peptide derivative with modified N-terminal charge |
AU2014204193A AU2014204193A1 (en) | 2013-01-03 | 2014-01-03 | Insulinotropic peptide derivative with modified N-terminal charge |
MX2015008596A MX2015008596A (es) | 2013-01-03 | 2014-01-03 | Derivado de peptido insulinotropico con la carga n-terminal modificada. |
CA2896934A CA2896934A1 (en) | 2013-01-03 | 2014-01-03 | Insulinotropic peptide derivative with modified n-terminus charge |
EP14735289.2A EP2942358A4 (en) | 2013-01-03 | 2014-01-03 | INSULINSEKRETIONEPEPIDE DERIVATIVE WITH MODIFIED STOCK AT N-TERMINUS |
JP2015551600A JP2016504379A (ja) | 2013-01-03 | 2014-01-03 | N−末端の電荷が改変されたインスリン分泌ペプチド誘導体 |
BR112015016159A BR112015016159A2 (pt) | 2013-01-03 | 2014-01-03 | derivado de peptídeo insulinotrópico com a carga do terminal n modificada. |
RU2015129010A RU2673179C2 (ru) | 2013-01-03 | 2014-01-03 | Производное инсулинотропного пептида с модифицированным N-концевым зарядом |
SG11201505197YA SG11201505197YA (en) | 2013-01-03 | 2014-01-03 | Insulinotropic peptide derivative with modified n-terminal charge |
CN201480003920.7A CN104918954A (zh) | 2013-01-03 | 2014-01-03 | N-末端电荷发生变化的胰岛素分泌肽衍生物 |
PH12015501491A PH12015501491A1 (en) | 2013-01-03 | 2015-06-29 | Insulinotropic peptide derivative with modified n-terminal charge |
SA515360713A SA515360713B1 (ar) | 2013-01-03 | 2015-07-01 | مـشـتـق ببـتـيد انتحـائي للأنسـولين ذي شـحنة مـعـدلة عـنـد N-Terminal |
IL239795A IL239795A0 (en) | 2013-01-03 | 2015-07-02 | Generation of an insulinotropic peptide with a modified n-terminal charge |
ZA2015/05509A ZA201505509B (en) | 2013-01-03 | 2015-07-31 | Insulinotropic peptide derivative with modified n-terminal charge |
HK15112191.5A HK1211309A1 (en) | 2013-01-03 | 2015-12-10 | Insulin secretion peptide derivative in which charge on n-terminus is modified n- |
US15/496,163 US20170226175A1 (en) | 2013-01-03 | 2017-04-25 | Insulinotropic peptide derivative with modified n-terminal charge |
AU2018203300A AU2018203300B2 (en) | 2013-01-03 | 2018-05-11 | Insulinotropic peptide derivative with modified N-terminal charge |
PH12018501319A PH12018501319A1 (en) | 2013-01-03 | 2018-06-20 | Insulinotropic peptide derivative with modified n-terminal charge |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130000766 | 2013-01-03 | ||
KR10-2013-0000766 | 2013-01-03 | ||
KR1020140000031A KR20140088837A (ko) | 2013-01-03 | 2014-01-02 | N-말단 전하가 변형된 인슐린 분비 펩티드 유도체 |
KR10-2014-0000031 | 2014-01-02 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/758,842 A-371-Of-International US9663565B2 (en) | 2013-01-03 | 2014-01-03 | Insulinotropic peptide derivative with modified N-terminal charge |
US15/496,163 Continuation US20170226175A1 (en) | 2013-01-03 | 2017-04-25 | Insulinotropic peptide derivative with modified n-terminal charge |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014107035A1 true WO2014107035A1 (ko) | 2014-07-10 |
Family
ID=51737214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/000025 WO2014107035A1 (ko) | 2013-01-03 | 2014-01-03 | N-말단 전하가 변형된 인슐린 분비 펩티드 유도체 |
Country Status (20)
Country | Link |
---|---|
US (2) | US9663565B2 (ko) |
EP (2) | EP3281951A1 (ko) |
JP (2) | JP2016504379A (ko) |
KR (1) | KR20140088837A (ko) |
CN (1) | CN104918954A (ko) |
AR (1) | AR094358A1 (ko) |
AU (2) | AU2014204193A1 (ko) |
BR (1) | BR112015016159A2 (ko) |
CA (1) | CA2896934A1 (ko) |
CO (1) | CO7461128A2 (ko) |
HK (1) | HK1211309A1 (ko) |
IL (1) | IL239795A0 (ko) |
MX (1) | MX2015008596A (ko) |
PH (2) | PH12015501491A1 (ko) |
RU (1) | RU2673179C2 (ko) |
SA (1) | SA515360713B1 (ko) |
SG (1) | SG11201505197YA (ko) |
TW (1) | TW201441253A (ko) |
WO (1) | WO2014107035A1 (ko) |
ZA (1) | ZA201505509B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4219565A1 (en) | 2014-06-05 | 2023-08-02 | Hanmi Pharm. Co., Ltd. | Method for decreasing immunogenicity of protein and peptide |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200262887A1 (en) | 2018-11-30 | 2020-08-20 | Opko Ireland Global Holdings, Ltd. | Oxyntomodulin peptide analog formulations |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR910700262A (ko) * | 1988-12-23 | 1991-03-14 | 안네 제케르 | 사람 인슐린 유사체 |
WO1997046584A1 (de) | 1996-06-05 | 1997-12-11 | Boehringer Mannheim Gmbh | Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel |
WO1999007404A1 (en) | 1997-08-08 | 1999-02-18 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
WO2001004156A1 (en) * | 1999-07-12 | 2001-01-18 | Zealand Pharmaceuticals A/S | Peptides that lower blood glucose levels |
US20080119390A1 (en) | 2001-02-26 | 2008-05-22 | Yeda Research Development Co., Ltd. | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
KR20080064750A (ko) * | 2007-01-05 | 2008-07-09 | 한미약품 주식회사 | 면역글로불린 단편을 이용한 인슐린분비 펩타이드 약물결합체 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3728515B2 (ja) * | 1994-10-24 | 2005-12-21 | 泰信 吉開 | 医薬組成物 |
US5688489A (en) * | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
KR101135244B1 (ko) * | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
US8263084B2 (en) * | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
PL1817048T3 (pl) * | 2004-11-12 | 2014-07-31 | Novo Nordisk As | Stabilne preparaty peptydów insulinotropowych |
JP2008013452A (ja) * | 2006-07-04 | 2008-01-24 | Akira Awaya | 医薬組成物 |
JP2009019027A (ja) | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
US20100020445A1 (en) * | 2008-07-25 | 2010-01-28 | Brian Thornton | Operational-shock performance in a disk drive by maintaining servo signal |
CN102348723A (zh) * | 2008-12-05 | 2012-02-08 | 安吉奥开米公司 | 肽治疗剂轭合物及其应用 |
DE102009007381A1 (de) * | 2009-01-29 | 2010-08-05 | Amp-Therapeutics Gmbh & Co. Kg | Antibiotische Peptide |
HUE030373T2 (en) * | 2009-03-20 | 2017-05-29 | Hanmi Science Co Ltd | A method for producing a site-specific conjugate of a physiologically active polypeptide |
UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії |
-
2014
- 2014-01-02 KR KR1020140000031A patent/KR20140088837A/ko not_active IP Right Cessation
- 2014-01-03 BR BR112015016159A patent/BR112015016159A2/pt not_active IP Right Cessation
- 2014-01-03 MX MX2015008596A patent/MX2015008596A/es unknown
- 2014-01-03 RU RU2015129010A patent/RU2673179C2/ru not_active IP Right Cessation
- 2014-01-03 AR ARP140100024A patent/AR094358A1/es unknown
- 2014-01-03 US US14/758,842 patent/US9663565B2/en active Active
- 2014-01-03 AU AU2014204193A patent/AU2014204193A1/en not_active Abandoned
- 2014-01-03 EP EP17192872.4A patent/EP3281951A1/en not_active Withdrawn
- 2014-01-03 JP JP2015551600A patent/JP2016504379A/ja active Pending
- 2014-01-03 TW TW103100155A patent/TW201441253A/zh unknown
- 2014-01-03 EP EP14735289.2A patent/EP2942358A4/en not_active Withdrawn
- 2014-01-03 CN CN201480003920.7A patent/CN104918954A/zh active Pending
- 2014-01-03 WO PCT/KR2014/000025 patent/WO2014107035A1/ko active Application Filing
- 2014-01-03 SG SG11201505197YA patent/SG11201505197YA/en unknown
- 2014-01-03 CA CA2896934A patent/CA2896934A1/en not_active Abandoned
-
2015
- 2015-06-29 PH PH12015501491A patent/PH12015501491A1/en unknown
- 2015-07-01 SA SA515360713A patent/SA515360713B1/ar unknown
- 2015-07-02 IL IL239795A patent/IL239795A0/en unknown
- 2015-07-10 CO CO15159985A patent/CO7461128A2/es unknown
- 2015-07-31 ZA ZA2015/05509A patent/ZA201505509B/en unknown
- 2015-12-10 HK HK15112191.5A patent/HK1211309A1/xx unknown
-
2017
- 2017-04-25 US US15/496,163 patent/US20170226175A1/en not_active Abandoned
-
2018
- 2018-05-11 AU AU2018203300A patent/AU2018203300B2/en not_active Ceased
- 2018-06-20 PH PH12018501319A patent/PH12018501319A1/en unknown
-
2019
- 2019-02-01 JP JP2019016968A patent/JP2019081777A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR910700262A (ko) * | 1988-12-23 | 1991-03-14 | 안네 제케르 | 사람 인슐린 유사체 |
WO1997046584A1 (de) | 1996-06-05 | 1997-12-11 | Boehringer Mannheim Gmbh | Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel |
WO1999007404A1 (en) | 1997-08-08 | 1999-02-18 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
WO2001004156A1 (en) * | 1999-07-12 | 2001-01-18 | Zealand Pharmaceuticals A/S | Peptides that lower blood glucose levels |
US20080119390A1 (en) | 2001-02-26 | 2008-05-22 | Yeda Research Development Co., Ltd. | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
KR20080064750A (ko) * | 2007-01-05 | 2008-07-09 | 한미약품 주식회사 | 면역글로불린 단편을 이용한 인슐린분비 펩타이드 약물결합체 |
Non-Patent Citations (5)
Title |
---|
CHAN, ANNA ON-YEE ET AL.: "Modification of N-terminal a -amino groups of peptides and proteins using ketenes", JACS, vol. 134, no. 5, 8 February 2012 (2012-02-08), pages 2589 - 2598, XP002742983, DOI: 10.1021/JA208009R * |
FONDA, IRENA ET AL.: "Improvement of potential therapeutic value of tumor necrosis- a (TNF- a) by charge modulation in the tip region", EUR. CYTOKINE NETW., vol. 16, no. 1, 1 March 2005 (2005-03-01), pages 17 - 26, XP055261126 * |
GALLWITZ ET AL., REGULATORY PEPTIDE, vol. 79, 1999, pages 93 - 102 |
GALLWITZ ET AL., REGULATORY PEPTIDE, vol. 86, 2000, pages 103 - 111 |
See also references of EP2942358A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4219565A1 (en) | 2014-06-05 | 2023-08-02 | Hanmi Pharm. Co., Ltd. | Method for decreasing immunogenicity of protein and peptide |
Also Published As
Publication number | Publication date |
---|---|
CN104918954A (zh) | 2015-09-16 |
KR20140088837A (ko) | 2014-07-11 |
PH12015501491B1 (en) | 2015-09-28 |
AU2018203300B2 (en) | 2019-08-15 |
EP2942358A4 (en) | 2016-06-01 |
SA515360713B1 (ar) | 2017-08-13 |
MX2015008596A (es) | 2015-09-04 |
IL239795A0 (en) | 2015-08-31 |
ZA201505509B (en) | 2016-07-27 |
PH12018501319A1 (en) | 2021-02-22 |
PH12015501491A1 (en) | 2015-09-28 |
AR094358A1 (es) | 2015-07-29 |
US20170226175A1 (en) | 2017-08-10 |
HK1211309A1 (en) | 2016-05-20 |
EP3281951A1 (en) | 2018-02-14 |
EP2942358A1 (en) | 2015-11-11 |
BR112015016159A2 (pt) | 2017-07-11 |
SG11201505197YA (en) | 2015-08-28 |
US20150329611A1 (en) | 2015-11-19 |
JP2016504379A (ja) | 2016-02-12 |
US9663565B2 (en) | 2017-05-30 |
CA2896934A1 (en) | 2014-07-10 |
RU2015129010A (ru) | 2017-02-06 |
TW201441253A (zh) | 2014-11-01 |
RU2673179C2 (ru) | 2018-11-22 |
JP2019081777A (ja) | 2019-05-30 |
CO7461128A2 (es) | 2015-11-30 |
AU2014204193A1 (en) | 2015-08-13 |
AU2018203300A1 (en) | 2018-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2442792C2 (ru) | Производное инсулинотропного пептида, содержащее модифицированную n-концевую аминокислоту | |
WO2012165915A2 (en) | Composition for treating diabetes comprising long-acting insulin conjugate and long-acting insulinotropic peptide conjugate | |
WO2014107035A1 (ko) | N-말단 전하가 변형된 인슐린 분비 펩티드 유도체 | |
US20040127412A1 (en) | Modified GLP-1 peptides with increased biological potency |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14735289 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2896934 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12015501491 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14758842 Country of ref document: US Ref document number: MX/A/2015/008596 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2015551600 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 239795 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 122019024839 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15159985 Country of ref document: CO |
|
REEP | Request for entry into the european phase |
Ref document number: 2014735289 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014735289 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201504608 Country of ref document: ID |
|
ENP | Entry into the national phase |
Ref document number: 2015129010 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014204193 Country of ref document: AU Date of ref document: 20140103 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015016159 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015016159 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150703 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12018501319 Country of ref document: PH |